Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$22.88 - $39.45 $157,574 - $271,692
-6,887 Closed
0 $0
Q4 2021

Feb 10, 2022

SELL
$35.2 - $52.6 $258,825 - $386,767
-7,353 Reduced 51.64%
6,887 $271,000
Q3 2021

Nov 10, 2021

SELL
$46.35 - $59.75 $198,934 - $256,447
-4,292 Reduced 23.16%
14,240 $695,000
Q2 2021

Aug 11, 2021

SELL
$47.2 - $67.81 $200,505 - $288,056
-4,248 Reduced 18.65%
18,532 $973,000
Q1 2021

May 12, 2021

BUY
$30.93 - $59.48 $672,944 - $1.29 Million
21,757 Added 2126.78%
22,780 $1.27 Million
Q4 2020

Feb 10, 2021

SELL
$18.53 - $31.5 $135,398 - $230,170
-7,307 Reduced 87.72%
1,023 $32,000
Q3 2020

Nov 13, 2020

SELL
$14.68 - $19.12 $657,385 - $856,212
-44,781 Reduced 84.32%
8,330 $154,000
Q2 2020

Aug 12, 2020

SELL
$8.5 - $15.82 $1.11 Million - $2.06 Million
-130,166 Reduced 71.02%
53,111 $734,000
Q1 2020

May 14, 2020

SELL
$7.25 - $19.22 $2.11 Million - $5.58 Million
-290,357 Reduced 61.3%
183,277 $1.68 Million
Q4 2019

Feb 12, 2020

BUY
$13.77 - $19.2 $1.52 Million - $2.12 Million
110,222 Added 30.33%
473,634 $8.24 Million
Q3 2019

Nov 12, 2019

SELL
$14.93 - $19.83 $619,624 - $822,984
-41,502 Reduced 10.25%
363,412 $5.5 Million
Q2 2019

Aug 09, 2019

SELL
$15.01 - $18.89 $630,645 - $793,663
-42,015 Reduced 9.4%
404,914 $7.65 Million
Q1 2019

May 15, 2019

BUY
$16.23 - $20.29 $1.54 Million - $1.92 Million
94,741 Added 26.9%
446,929 $7.83 Million
Q4 2018

Feb 14, 2019

BUY
$10.77 - $18.44 $117,974 - $201,991
10,954 Added 3.21%
352,188 $6.13 Million
Q3 2018

Nov 13, 2018

BUY
$9.1 - $14.8 $3.06 Million - $4.98 Million
336,485 Added 7085.39%
341,234 $4.83 Million
Q1 2018

May 15, 2018

SELL
$5.7 - $12.3 $84,217 - $181,732
-14,775 Reduced 75.68%
4,749 $47,000
Q4 2017

Feb 14, 2018

BUY
$3.65 - $5.98 $71,262 - $116,753
19,524
19,524 $106,000

Others Institutions Holding VCEL

About Vericel Corp


  • Ticker VCEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,178,000
  • Market Cap $2.6B
  • Description
  • Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for t...
More about VCEL
Track This Portfolio

Track Panagora Asset Management Inc Portfolio

Follow Panagora Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Panagora Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Panagora Asset Management Inc with notifications on news.